Latest Insider Transactions at Veracyte, Inc. (VCYT)
This section provides a real-time view of insider transactions for Veracyte, Inc. (VCYT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of VERACYTE, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of VERACYTE, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 06
2025
|
Phillip G. Febbo Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
8,349
-8.28%
|
$300,564
$36.02 P/Share
|
|
Oct 01
2025
|
Annie Mc Guire SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
2,160
-2.36%
|
$75,600
$35.0 P/Share
|
|
Oct 01
2025
|
Robert S Epstein Director |
SELL
Open market or private sale
|
Direct |
21,473
-25.59%
|
$751,555
$35.08 P/Share
|
|
Oct 01
2025
|
Robert S Epstein Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+10.65%
|
$70,000
$7.94 P/Share
|
|
Oct 01
2025
|
John Leite Chief Commercial Officer-CLIA |
SELL
Open market or private sale
|
Direct |
2,539
-2.77%
|
$88,865
$35.0 P/Share
|
|
Sep 19
2025
|
Annie Mc Guire SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
2,283
-2.43%
|
$75,339
$33.69 P/Share
|
|
Sep 04
2025
|
Marc Stapley Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,667
-2.24%
|
$230,010
$30.41 P/Share
|
|
Sep 02
2025
|
Rebecca Chambers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,371
-3.88%
|
$161,130
$30.11 P/Share
|
|
Sep 02
2025
|
Marc Stapley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,914
-2.26%
|
$237,420
$30.11 P/Share
|
|
Sep 02
2025
|
Annie Mc Guire SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,507
-3.6%
|
$105,210
$30.11 P/Share
|
|
Sep 02
2025
|
John Leite Chief Commercial Officer-CLIA |
SELL
Payment of exercise price or tax liability
|
Direct |
2,902
-3.07%
|
$87,060
$30.11 P/Share
|
|
Sep 02
2025
|
Phillip G. Febbo Chief Scientific & Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,955
-2.85%
|
$88,650
$30.11 P/Share
|
|
Sep 02
2025
|
Jonathan Wygant VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,648
-3.4%
|
$49,440
$30.11 P/Share
|
|
Jun 18
2025
|
Eliav Barr Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,321
+15.4%
|
-
|
|
Jun 18
2025
|
Robert S Epstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,321
+11.2%
|
-
|
|
Jun 18
2025
|
Evan/ Fa Jones Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,321
+17.59%
|
-
|
|
Jun 18
2025
|
Jens Holstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,321
+20.04%
|
-
|
|
Jun 18
2025
|
Karin Eastham Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,321
+28.64%
|
-
|
|
Jun 18
2025
|
David Brent Shafer Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,321
+26.52%
|
-
|
|
Jun 18
2025
|
Thomas F. Miller Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,321
+26.52%
|
-
|
|
Jun 18
2025
|
Muna Bhanji Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,321
+19.17%
|
-
|
|
Jun 13
2025
|
Muna Bhanji Director |
SELL
Open market or private sale
|
Direct |
4,589
-13.27%
|
$119,314
$26.67 P/Share
|
|
Jun 13
2025
|
Karin Eastham Director |
SELL
Open market or private sale
|
Direct |
4,590
-24.81%
|
$119,340
$26.66 P/Share
|
|
Jun 04
2025
|
John Leite Chief Commercial Officer-CLIA |
SELL
Open market or private sale
|
Direct |
2,809
-2.89%
|
$75,843
$27.2 P/Share
|
|
Jun 02
2025
|
Marc Stapley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,399
-2.62%
|
$244,374
$26.74 P/Share
|
|
Jun 02
2025
|
Phillip G. Febbo Chief Scientific & Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,955
-2.77%
|
$76,830
$26.74 P/Share
|
|
Jun 02
2025
|
Jonathan Wygant VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,848
-3.71%
|
$48,048
$26.74 P/Share
|
|
Jun 02
2025
|
John Leite Chief Commercial Officer-CLIA |
SELL
Payment of exercise price or tax liability
|
Direct |
2,900
-2.89%
|
$75,400
$26.74 P/Share
|
|
Jun 02
2025
|
Rebecca Chambers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,370
-3.73%
|
$139,620
$26.74 P/Share
|
|
Jun 02
2025
|
Annie Mc Guire SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,505
-3.49%
|
$91,130
$26.74 P/Share
|
|
Mar 07
2025
|
John Leite Chief Commercial Officer-CLIA |
SELL
Open market or private sale
|
Direct |
7,411
-3.49%
|
$229,741
$31.5 P/Share
|
|
Mar 06
2025
|
Marc Stapley Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,601
+20.17%
|
-
|
|
Mar 06
2025
|
Annie Mc Guire SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
30,200
+23.1%
|
-
|
|
Mar 06
2025
|
John Leite Chief Commercial Officer-CLIA |
BUY
Grant, award, or other acquisition
|
Direct |
36,240
+25.18%
|
-
|
|
Mar 06
2025
|
Rebecca Chambers Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,200
+17.35%
|
-
|
|
Mar 06
2025
|
Phillip G. Febbo Chief Scientific & Med Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,160
+18.46%
|
-
|
|
Mar 06
2025
|
Jonathan Wygant VP, Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,288
+21.08%
|
-
|
|
Mar 04
2025
|
Annie Mc Guire SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
1,142
-1.6%
|
$37,686
$33.69 P/Share
|
|
Mar 04
2025
|
Marc Stapley Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
52,697
-5.73%
|
$1,739,001
$33.7 P/Share
|
|
Mar 04
2025
|
Phillip G. Febbo Chief Scientific & Med Officer |
SELL
Open market or private sale
|
Direct |
8,037
-4.54%
|
$265,221
$33.41 P/Share
|
|
Mar 02
2025
|
Annie Mc Guire SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
8,255
-10.36%
|
$280,670
$34.76 P/Share
|
|
Mar 02
2025
|
Rebecca Chambers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,070
-8.87%
|
$376,380
$34.76 P/Share
|
|
Mar 02
2025
|
Jonathan Wygant VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,301
-10.55%
|
$146,234
$34.76 P/Share
|
|
Mar 02
2025
|
Phillip G. Febbo Chief Scientific & Med Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,754
-6.94%
|
$229,636
$34.76 P/Share
|
|
Mar 02
2025
|
Marc Stapley Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
20,324
-5.96%
|
$691,016
$34.76 P/Share
|
|
Mar 02
2025
|
John Leite Chief Commercial Officer-CLIA |
SELL
Payment of exercise price or tax liability
|
Direct |
7,650
-9.68%
|
$260,100
$34.76 P/Share
|
|
Feb 27
2025
|
Annie Mc Guire SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
7,000
-8.07%
|
$231,000
$33.84 P/Share
|
|
Feb 27
2025
|
Annie Mc Guire SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
13,466
+13.44%
|
-
|
|
Feb 27
2025
|
Rebecca Chambers Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,911
-8.71%
|
$393,063
$33.84 P/Share
|
|
Feb 27
2025
|
Rebecca Chambers Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
23,170
+14.49%
|
-
|